Trials / Completed
CompletedNCT05364021
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Longboard Pharmaceuticals · Industry
- Sex
- All
- Age
- 12 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.
Detailed description
This is a randomized, double-blind, parallel-group, dose-escalation, placebo-controlled study of LP352 in adults and adolescents with developmental and epileptic encephalopathies (DEE) with an average of ≥ 4 observed/countable motor seizures per 4-week period during the 12 weeks before screening while on stable antiseizure medicine (ASM). Subjects will be randomized 4:1 to LP352 or placebo. The study will have a baseline period of 28 days, followed by a 15 day up-titration period during which time subjects will titrate up to their highest tolerated doses, and a 60-day maintenance period. After Day 75, subjects will be tapered down over a period of up to 15 days, with a follow-up visit 30 days after last dose. Enrolled subjects will be allowed to continue treatment with up to 4 concomitant ASMs at a stable dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LP352 | LP352 administered three times daily, orally or through G-tube |
| DRUG | Placebo | Matching placebo for LP352 administered three times daily, orally or through G-tube |
Timeline
- Start date
- 2022-03-03
- Primary completion
- 2023-11-16
- Completion
- 2023-11-20
- First posted
- 2022-05-06
- Last updated
- 2024-11-08
Locations
34 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05364021. Inclusion in this directory is not an endorsement.